Background: Multi-center, randomized-controlled trials and observational studies have demonstrated
that, in severe asthmatic patients receiving omalizumab treatment, the frequency of exacerbations, the number of
urgent adverse events, and the need for oral steroids tend to decrease.
Materials and Methods: This study included a total of 32 patients. The patients were divided into two groups as
Group IA (pre-omalizumab) and Group IB (post-omalizumab). Serum IL-25 and IL-33 levels were measured and
the number of emergency admissions, length of hospitalization (day), Asthma Control Test (ACT) scores, eosinophil
cationic protein (ECP), and fractional exhaled nitric oxide (FeNO) value were analyzed.
Results: ACT and FeNO values increased after omalizumab treatment, while IL-33, IL-25 levels decreased after
the completion of omalizumab treatment. Furthermore, there was a weak, positive, and significant relationship
between the changes in the ECP levels and IL-33 levels (r=0.38, p=0.03).
Conclusion: To the best of our knowledge, this is the first study to compare circulating IL-25 and IL-33 levels
with specific IgE synthesis in the literature. Multivariate correlation analysis showed that the changes in serum
IL-33 levels were significantly correlated with the changes in the mite sIgE levels and length of hospital stay
(Fmodel=11.2, p=0.01, r2=0.45). On the other hand, there was no significant relationship between the other variables
and changes in the IL-25 levels.